Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study.
Oliva A, Cogliati Dezza F, Petrucci F, Romani FE, Morviducci M, Mirabelli FM, Cancelli F, Valeriani E, Marcelli G, Pugliese F, Turriziani O, Ricci P, Venditti M, Palange P, Mastroianni CM. Oliva A, et al. Clin Exp Med. 2023 Oct;23(6):2275-2285. doi: 10.1007/s10238-023-01027-y. Epub 2023 Mar 3. Clin Exp Med. 2023. PMID: 36867292 Free PMC article.
Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring.
Barone R, Conti M, Giorgi B, Gatti M, Cojutti PG, Viale P, Pea F. Barone R, et al. Antibiotics (Basel). 2023 Apr 6;12(4):719. doi: 10.3390/antibiotics12040719. Antibiotics (Basel). 2023. PMID: 37107082 Free PMC article.
Meropenem (MRP)-Vaborbactam (VBR) is a novel beta-lactam/beta-lactamase inhibitor used for the management of difficult-to-treat Gram-negative infections. Among critically ill patients, MRP-VBR shows remarkable inter-individual variability in pharmacokinetic behavior, thus …
Meropenem (MRP)-Vaborbactam (VBR) is a novel beta-lactam/beta-lactamase inhibitor used for the management of difficult-to-treat Gram- …